Basilea Pharmaceutica (LTS:0QNA) Net Issuance of Preferred Stock : CHF0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Basilea Pharmaceutica Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Basilea Pharmaceutica's net issuance of preferred for the six months ended in Dec. 2023 was CHF0.0 Mil. The number is 0, which means that Basilea Pharmaceutica has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Basilea Pharmaceutica's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was CHF0.0 Mil.

Basilea Pharmaceutica Net Issuance of Preferred Stock Historical Data

The historical data trend for Basilea Pharmaceutica's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Net Issuance of Preferred Stock Chart

Basilea Pharmaceutica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Basilea Pharmaceutica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Basilea Pharmaceutica Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.0 Mil.

Basilea Pharmaceutica Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Basilea Pharmaceutica (LTS:0QNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (LTS:0QNA) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

BSLNz:UK BSLN:Switzerland

Address

Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058

Website

https://www.basilea.com

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (LTS:0QNA) Headlines

No Headlines